Showing 2191-2200 of 4064 results for "".
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
https://reachmd.com/programs/cme/enhancing-collaborative-care-in-retinal-diseases-a-focus-on-injection-therapies/37715/Explore strategies to improve retinal disease referrals and adherence to anti-VEGF therapy through interdisciplinary collaboration.Practical Strategies for Improving Adherence in Psoriasis Care
https://reachmd.com/programs/frontlines-psoriasis/strategies-improve-adherence-psoriasis/39954/In psoriasis management, patient adherence is a persistent challenge, especially with topical therapies for mild involvement. Ryan Quigley sits down with Dr. Steve Feldman to explore evidence-based, real-world strategies to support these patients and promote long-term success. Dr. Feldman is a profeMarketing “Ozempic Makeovers”
https://reachmd.com/ma-issues-index/march-april-2026-issue/marketing-ozempic-makeovers/56640/How practices can adapt to rising GLP-1 RA weight loss demandFractional Micro-Coring for Weight Loss Laxity
https://reachmd.com/ma-issues-index/march-april-2026-issue/fractional-micro-coring-for-weight-loss-laxity/56631/Fractional excision for the removal of skin laxityKeep Autoimmune Rheumatic Disease On Your DED Radar
https://reachmd.com/podcasts/the-mod-pod/keep-autoimmune-rheumatic-disease-on-your-ded-radar/56396/Here’s what to look out for—and how to proceed if you find it.The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
https://reachmd.com/programs/cme/the-ambulatory-hfref-blind-spot-proactively-reducing-cv-mortality-risk-despite-optimized-gdmt/48810/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
https://reachmd.com/programs/global-neurology-academy/beyond-the-primary-endpoint-what-oceanic-stroke-subtype-analyses-reveal-about-asundexians-potential/54416/Dive into stroke subtype data from OCEANIC-STROKE to see how asundexian's effects vary across clinically distinct patient populations.OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
https://reachmd.com/programs/global-neurology-academy/oceanic-stroke-results-asundexian-for-secondary-stroke-prevention-after-acute-non-cardioembolic-stroke-or-high-risk-tia/54141/Explore key findings from OCEANIC-STROKE on asundexian’s role in reducing recurrent stroke without added bleeding risk.Examining Airway Tolerability of a Climate Conscious Inhaler
https://reachmd.com/programs/clinicians-roundtable/airway-tolerability-climate-conscious-inhaler/54178/It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
https://reachmd.com/programs/cme/it-takes-a-village-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37714/Review a case of geographic atrophy highlighting care coordination gaps and quality improvement opportunities in patients who relocate seasonally for retina care.